Unilumin, Megapixel VR and Userful Certify Advanced AV and LED Solutions for the Enterprise
2.2.2023 09:00:00 EET | Business Wire | Press release
Userful Corporation, the leading Platform-as-a-Service (PaaS) provider in the Enterprise AV-over-IP market, and Unilumin a world-class LED solution provider of high-quality LED display and lighting products alongside Megapixel VR have certified the integration of their advanced AV technologies.
This validation enables enterprise customers to modernize AV and LED deployments for control rooms, digital signage, meeting spaces and artistic video walls.
Unilumin’s award-winning, market-proven LED display technology and manufacturing expertise along with its successful deployment history pair strongly with Userful’s software-defined AV-over-IP platform to deliver an unsurpassed, centrally managed, secure, and scalable solution for a multitude of AV business applications.
“We are pleased to certify this solution with Userful to further enhance our DV-LED + Megapixel platforms and to provide customers an integrated choice for the broad range of enterprise applications that employ DV-LED,” said Unilumin President, Chris Danley.
“Through the testing and certification of our technologies, Unilumin, Megapixel, and Userful are advancing enterprise applications and providing assurances to AV and IT departments that our solution will meet and exceed expectations,” said Megapixel CEO Jeremy Hochman.
“As we continue to advance our next-generation AV platform, we are excited to collaborate with technology leaders to create best-in-class solutions. Integrating Unilumin and Megapixel’s state-of-the-art displays and controllers with Userful’s platform will provide a superior and unsurpassed solution for the digitally transformed enterprise,” said John Marshall, CEO, Userful.
A certified solution brief that provides an overview and specifications for this multiproduct solution can be found at userful.com/unilumin. The solution will be presented publicly in Unilumin’s booth at InfoComm 2023 in Orlando, Florida.
About Userful
Userful is the world’s leading platform-as-a-service provider in the Enterprise AV-over-IP market—the fastest-growing segment of the IT industry, forecasted to grow from today’s $3B to $51B by 2027, a 60 percent 5-year CAGR. Userful’s software-defined solution is disrupting the market with a Platform-as-a-Service (PaaS) model that allows customers to choose from a suite of highly-integrated AV applications (SaaS offerings, secure, SSO, integrated UI) to support modern service needs across the enterprise. From corporate signage to control room solutions to streaming platforms and data metrics, Userful's solutions enable modernized business operations for IT leaders and the functional departments they support. Userful helps organizations advance the way they work, learn and govern with secure, scalable, and centrally managed solutions for employee and customer engagement worldwide.
About Unilumin
Unilumin is a leading manufacturer of LED display products. In the field of Virtual Production, Unilumin has provided products and services for various industries such as film, XR, broadcast, and commercial. With an office and showroom in NYC and a 36,000+ sq. ft. Orlando Florida facility featuring a service repair center and "Experience Center" showroom, Unilumin is adhering to the corporate mission of "Together, for a Brighter Future", by providing cutting-edge LED products with an advanced sense of designs and one-stop solutions.
About Megapixel VR
Megapixel VR is an innovative technology partner dedicated to delivering fast-tracked, customized, state-of-the-art LED processing and monitoring to the world’s leading entertainment, film & TV, and architectural applications. Superior product design development, manufacturing expertise, and successful deployment, Megapixel delivers unsurpassed visual performance for any project and looks forward to making the world’s next iconic projects a reality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006123/en/
Contact information
Danielle Alfaro
communications@userful.com
403-923-6723
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom